https://www.zerohedge.com/markets/trump-netanyahu-differences-good-cop-bad-cop-routine

https://breakingthenews.net/Article/Oil-down-2-as-Middle-East-escalation-stops/66468673

https://breakingthenews.net/Article/IDF-strikes-Hamas-naval-HQ-kills-commander/66468397

https://breakingthenews.net/Article/China-will-not-restart-rare-earths-sales-to-Japan/66468426

https://www.morningstar.com/news/accesswire/1174386msn/alzecure-pharma-enters-into-a-collaboration-and-out-licensing-agreement-with-lilly-for-alzheimers-project

Gilead, Merck HIV Combination Meets Primary Endpoint in Two Phase 3 Trials

Novel Investigational Combination Pairs Merck’s Islatravir, a Next-Generation Nucleoside Analog with Distinct Mechanisms of Action, Including Reverse Transcriptase Translocation Inhibition, with Gilead’s Lenacapavir, a First-in-Class Capsid Inhibitor that Disrupts HIV at Multiple Stages of its Lifecycle –

– Islatravir/Lenacapavir has the Potential to be the First Approved Long-Acting Oral HIV Treatment Taken Once-Weekly –

https://sg.finance.yahoo.com/news/gilead-merck-announce-positive-topline-203500265.html

GSK in talks to buy cancer biotech Nuvalent for more than $9 billion: FT

 GSK is reportedly in talks to acquire clinical‑stage cancer biotech Nuvalent for more than $9 billion, according to the Financial Times; the deal—if true—would mark a major expansion of GSK’s oncology pipeline. Nuvalent’s market cap stands around $8–8.5 billion

https://www.globalbankingandfinance.com/gsk-talks-buy-cancer-biotech-nuvalent-9-billion-ft-reports/